1800-272-662
Shopping Cart 0
countryflagAU
Login

Dimerix Ltd

Healthcare AU DXB

0.35AUD
-0.02(5.41%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.340.36
LowHigh

52 Week Range

0.340.79
LowHigh

Fundamentals

  • Previous Close 0.37
  • Market Cap216.14M
  • Volume1677729
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.29390M
  • Revenue TTM7.42M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 7.42M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -31.68214M -17.07508M -13.80282M -10.49058M -6.37173M
Minority interest - - - - -
Net income -13.25172M -17.07500M -13.80282M -10.49295M -6.37023M
Selling general administrative 4.89M 3.12M 2.17M 2.39M 1.44M
Selling and marketing expenses - 1.42M 0.07M - -
Gross profit 1.25M 0.58M 8.98M - -
Reconciled depreciation 0.12M 0.05M 0.06M 0.05M 0.04M
Ebit -36.34135M -25.00775M -22.82334M -16.95640M -10.92817M
Ebitda -36.21779M -24.95900M -22.76733M -16.90586M -10.88357M
Depreciation and amortization 0.12M 0.05M 0.06M 0.05M 0.04M
Non operating income net other - - - - -
Operating income -36.34135M -25.23580M -13.83961M -16.95640M -10.92817M
Other operating expenses 37.60M 25.64M 22.82M 16.96M 10.93M
Interest expense - - - 0.00237M 0.00000M
Tax provision -18.43042M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.33M 0.18M 0.04M 0.00237M 0.00151M
Net interest income 0.33M 0.18M 0.04M 0.00237M 0.00151M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -18.43042M -7.93200M -0.03679M 0.00237M -0.00151M
Total revenue 1.25M 0.58M 8.98M 0.00237M 0.00151M
Total operating expenses 37.60M 25.64M 22.82M 16.96M 10.93M
Cost of revenue - - - - -
Total other income expense net 0.33M 8.16M 8.98M 6.47M 4.56M
Discontinued operations - - - - -
Net income from continuing ops -13.25172M -17.07508M -13.80282M -10.49058M -6.37173M
Net income applicable to common shares -13.25172M -17.07508M -13.80282M -10.49058M -6.37173M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 91.18M 32.08M 17.76M 16.50M 9.42M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.26M 0.02M 0.07M 0.04M
Total liab 77.80M 13.89M 11.79M 2.07M 7.95M
Total stockholder equity 13.38M 18.19M 5.96M 14.42M 1.47M
Deferred long term liab - - - - -
Other current liab 4.23M 2.40M 6.62M 0.91M 5.43M
Common stock - 83.38M 55.49M 50.90M 28.39M
Capital stock 90.92M 83.38M 55.49M 50.90M 28.39M
Retained earnings -82.42777M -69.17605M -52.10097M -38.29815M -27.80757M
Other liab - - 0.04M 0.03M -
Good will - - - - -
Other assets - - - - -
Cash 68.28M 22.14M 7.99M 9.63M 5.25M
Cash and equivalents - - 7.99M 9.63M 5.25M
Total current liabilities 22.16M 3.36M 11.76M 2.02M 7.95M
Current deferred revenue - 0.57M -5.95781M -0.05212M -5.09309M
Net debt - -21.99178M -2.03398M -9.55666M -0.15700M
Short term debt - 0.08M 5.96M 0.05M 5.09M
Short long term debt - - 5.94M - 5.05M
Short long term debt total - 0.15M 5.96M 0.07M 5.09M
Other stockholder equity - - -3.38840M -12.59699M -0.58155M
Property plant equipment - - 0.00641M 0.00861M 0.00142M
Total current assets 72.18M 31.92M 17.75M 16.49M 9.42M
Long term investments - - - - -
Net tangible assets - - 5.96M 14.42M 1.47M
Short term investments - - - - -
Net receivables - 9.52M 9.55M 6.39M 4.01M
Long term debt - - - - -
Inventory - - 0.18M 0.40M 0.12M
Accounts payable 14.08M 0.31M 5.14M 1.11M 2.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 3.98M 2.57M 1.83M 0.89M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.00641M -0.00861M -0.00142M
Deferred long term asset charges - - - - -
Non current assets total 19.00M 0.16M 0.00641M 0.00861M 0.00142M
Capital lease obligations 0.10M 0.15M 0.02M 0.07M 0.04M
Long term debt total - - 0.00000M 0.02M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.02101M -0.01580M -0.00230M -0.01061M 0.00438M
Change to liabilities - - 3.64M -0.92150M 1.28M
Total cashflows from investing activities -0.02101M -0.01580M -0.00230M -0.01061M 0.00438M
Net borrowings - -2.84250M 6.29M -1.74743M 3.89M
Total cash from financing activities 7.42M 21.17M 11.07M 17.69M 3.83M
Change to operating activities - - 0.06M -0.24890M 0.02M
Net income -13.25172M -17.07508M -13.80282M -10.49058M -6.37173M
Change in cash 46.14M 14.15M -1.63796M 4.38M -2.53561M
Begin period cash flow 22.14M 7.99M 9.63M 5.25M 7.79M
End period cash flow 68.28M 22.14M 7.99M 9.63M 5.25M
Total cash from operating activities 39.05M -7.00401M -12.72866M -13.43594M -6.36044M
Issuance of capital stock 7.55M 25.71M 8.72M 20.68M 0.04M
Depreciation - 0.05M 0.06M 0.05M 0.04M
Other cashflows from investing activities - - - 0.00000M 0.01M
Dividends paid - - - 0.00140M 1.24M
Change to inventory - - - - -
Change to account receivables 5.63M 0.04M -3.16842M -2.33708M -1.54373M
Sale purchase of stock 7.55M -1.40296M -0.44461M -1.24001M -1.24001M
Other cashflows from financing activities -0.01512M -0.29093M 2.79M -0.04743M 4.85M
Change to netincome - - 0.49M 0.51M 0.20M
Capital expenditures 0.02M 0.02M 0.00230M 0.01M 0.00957M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 50.59M 7.97M -3.16842M -2.33708M -1.54373M
Stock based compensation - 1.41M 0.07M 0.13M 0.04M
Other non cash items -11.53898M 0.64M 1.02M -2.99590M -0.03331M
Free cash flow 39.03M -7.01981M -12.73096M -13.44655M -6.37001M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DXB
Dimerix Ltd		 -0.02 5.41% 0.35 - 10.78 29.95 21.32 23.96 -1.9424
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

Dimerix Ltd

425 Smith Street, Fitzroy, VIC, Australia, 3065

Key Executives

Name Title Year Born
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. CEO, MD & Director NA
Dr. Ashish Soman M.B.A., M.D., MBBS Chief Medical Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Sec. NA
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. Chief Scientific Advisor NA
Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB. Bus. Devel. Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964
Mr. Robert Shepherd Chief Commercialisation Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.